NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 58 filers reported holding NEUBASE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $69,700 | -61.2% | 376,758 | -60.2% | 0.00% | – |
| Q4 2022 | $179,867 | -57.1% | 945,674 | -10.7% | 0.00% | – |
| Q3 2022 | $419,000 | -62.3% | 1,059,054 | 0.0% | 0.00% | – |
| Q2 2022 | $1,112,000 | -44.1% | 1,059,054 | 0.0% | 0.00% | – |
| Q1 2022 | $1,991,000 | -48.1% | 1,059,054 | -22.4% | 0.00% | – |
| Q4 2021 | $3,834,000 | -22.3% | 1,364,634 | -0.1% | 0.00% | – |
| Q3 2021 | $4,932,000 | -20.7% | 1,366,330 | +5.3% | 0.00% | – |
| Q2 2021 | $6,217,000 | -12.3% | 1,297,848 | +35.4% | 0.00% | – |
| Q1 2021 | $7,086,000 | +9.6% | 958,831 | +3.7% | 0.00% | – |
| Q4 2020 | $6,465,000 | -7.1% | 924,901 | +0.9% | 0.00% | – |
| Q3 2020 | $6,957,000 | +516.2% | 916,553 | +612.8% | 0.00% | – |
| Q2 2020 | $1,129,000 | +285.3% | 128,588 | +212.9% | 0.00% | – |
| Q1 2020 | $293,000 | -1.0% | 41,097 | 0.0% | 0.00% | – |
| Q4 2019 | $296,000 | +44.4% | 41,097 | 0.0% | 0.00% | – |
| Q3 2019 | $205,000 | – | 41,097 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenlight Capital | 2,027,027 | $14,169,000 | 0.85% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 103,500 | $723,000 | 0.55% |
| Sio Capital Management, LLC | 293,699 | $2,053,000 | 0.42% |
| GSA CAPITAL PARTNERS LLP | 121,389 | $849,000 | 0.14% |
| Frontier Wealth Management LLC | 145,000 | $1,014,000 | 0.08% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 311,000 | $2,174,000 | 0.06% |
| Oak Grove Capital LLC | 19,175 | $134,000 | 0.04% |
| PREMIER ASSET MANAGEMENT LLC | 14,977 | $105,000 | 0.02% |
| Trexquant Investment LP | 15,479 | $108,000 | 0.01% |
| PILLAR PACIFIC CAPITAL MANAGEMENT LLC | 19,800 | $138,000 | 0.01% |